Network origin in Shashi Karan first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Extinct | Medical Specialties | 10 | |
PathoGenesis Corp
 PathoGenesis Corp BiotechnologyHealth Technology Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million.
7
| Subsidiary | Biotechnology | 7 |
MediaNet Digital, Inc.
 MediaNet Digital, Inc. Specialty TelecommunicationsCommunications MediaNet Digital, Inc. provides digital media fulfillment services. Its services include digital content solutions, content fulfillment services, content information services and integration options and tools. The company was founded in 1999 and is headquartered in Seattle, WA.
2
| Subsidiary | Specialty Telecommunications | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Shashi Karan via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Treasurer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director of Finance/CFO Corporate Officer/Principal | |
| University of Pennsylvania | College/University | Masters Business Admin Doctorate Degree | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| University of Alberta | College/University | Undergraduate Degree Director/Board Member | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Undergraduate Degree | |
| AC IMMUNE SA | Pharmaceuticals: Major | Chairman | |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Biotechnology | Chief Tech/Sci/R&D Officer | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| OVID THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| CODIAK BIOSCIENCES | Pharmaceuticals: Major | Chief Executive Officer | |
| University of Massachusetts Lowell | College/University | Undergraduate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Chairman | |
| PANACEA ACQUISITION CORP. II | Financial Conglomerates | Director/Board Member | |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Biotechnology | Director/Board Member | |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
| SANA BIOTECHNOLOGY, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree | |
| SEAGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Miscellaneous Commercial Services | Director/Board Member | |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director of Finance/CFO | |
| University of Edinburgh Business School | College/University | Masters Business Admin | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Director/Board Member | |
| NEVIS BRANDS INC. | Biotechnology | Director/Board Member | |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director of Finance/CFO | |
| HARPOON THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
Genesis Research & Development Corp. Ltd.
 Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | Financial Conglomerates | Corporate Officer/Principal | |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Doctorate Degree | |
| ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
Schwarz Pharma, Inc.
 Schwarz Pharma, Inc. Pharmaceuticals: MajorHealth Technology SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| E. R. Squibb & Sons LLC | Chief Tech/Sci/R&D Officer | ||
| PARATEK PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member | |
| State University of New York at Buffalo | College/University | Doctorate Degree | |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Biotechnology | Founder | |
| ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer |
Statistics
International
| United States | 45 |
| Canada | 3 |
| Switzerland | 2 |
| Netherlands | 2 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 33 |
| Consumer Services | 10 |
| Finance | 5 |
| Commercial Services | 3 |
| Health Services | 2 |
Operational
| Director/Board Member | 74 |
| Corporate Officer/Principal | 38 |
| Chief Tech/Sci/R&D Officer | 33 |
| Independent Dir/Board Member | 25 |
| Chief Executive Officer | 19 |
Most connected contacts
| Insiders | |
|---|---|
| Dan Spiegelman | 25 |
| Douglas Williams | 25 |
| Alan Montgomery | 18 |
| Matthew Gantz | 16 |
| Julia Eastland | 16 |
| Diana Hausman | 13 |
| Joanne Quan | 12 |
| Edward A. Taylor | 10 |
| D. Kirkpatrick | 9 |
| Michael Peter Short | 9 |
| S. Ken Tanaka | 8 |
| Stephen K. Burley | 7 |
| Alan McGlade | 7 |
| Jonathan Levinson | 6 |
| Alan R. Meyer | 6 |
- Stock Market
- Insiders
- Shashi Karan
- Company connections
